Mark Chin, MS, MBA

Mark Chin, investment manager at Arix Bioscience, currently sits on the board of Iterum Therapeutics, Harpoon Therapeutics and OptiKira. He was previously a principal at Longitude Capital, where he focused on investments in both private and public biotechnology and medical technology companies. Prior to Longitude, Chin was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies. Before BCG, he worked in corporate development at Gilead Sciences and market planning at Genentech. Chin has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.

    Search Investor Relations